Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BACHEM AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit, concentrating the company's current legal efforts into one specific channel. This singular focus indicates that the company is currently prioritizing a specific technical advancement within the Biotechnology & Pharmaceuticals field. The involvement of 1 distinct art unit suggests that the application is being reviewed by a specialized group of experts. This concentration simplifies the tracking of pending matters but increases the impact of any examiner's decision-making style.
The busiest examiner for this portfolio is JARET JAMES CREWS, who is handling 1 busiest examiner pending action. Because there is only 1 distinct examiner, the relationship between the applicant and the patent office is currently very direct. The 1 pending office action serves as the sole focal point for the company's immediate patent goals. Practitioners can focus their resources on addressing the specific concerns of this one examiner within the 1 distinct art unit. This focus on 1 busiest examiner pending action simplifies the administrative management of the active applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553868 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553868 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Oct 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBACHEM AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jaret James Crews has the most, with 1 of BACHEM AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
